Agenus reports melanoma trial data for drug combination BOT+BAL

May 21, 2026 5:00 PM

Agenus Inc. (NASDAQ: AGEN) presented Phase 2 trial data for its drug combination botensilimab and balstilimab in patients with advanced ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found